2024
Li-Fraumeni Syndrome: Imaging Features and Guidelines.
Gosangi B, Dixe de Oliveira Santo I, Keraliya A, Wang Y, Irugu D, Thomas R, Khandelwal A, Rubinowitz A, Bader A. Li-Fraumeni Syndrome: Imaging Features and Guidelines. RadioGraphics 2024, 44: e230202. PMID: 39024172, DOI: 10.1148/rg.230202.Peer-Reviewed Original ResearchConceptsLi-Fraumeni syndromeLifetime risk of cancerRare autosomal dominant familial cancer syndromeIncreased riskRisk of cancerTreated with total mastectomyAutosomal dominant familial cancer syndromeImaging features of tumorsFamilial cancer syndromeWhole-body MRIAnnual screeningFeatures of tumorsCancer syndromesLifetime riskP53 transcription factorLi-FraumeniAdrenocortical cancerTotal mastectomyPrimary cancerBreast malignancyImaging guidelinesBreast cancerGermline mutationsColon cancerManagement guidelinesProstate Cancer Foundation Screening Guidelines for Black Men in the United States.
Garraway I, Carlsson S, Nyame Y, Vassy J, Chilov M, Fleming M, Frencher S, George D, Kibel A, King S, Kittles R, Mahal B, Pettaway C, Rebbeck T, Rose B, Vince R, Winn R, Yamoah K, Oh W. Prostate Cancer Foundation Screening Guidelines for Black Men in the United States. NEJM Evidence 2024, 3: evidoa2300289. PMID: 38815168, DOI: 10.1056/evidoa2300289.Peer-Reviewed Original ResearchConceptsProstate-specific antigenBaseline PSA testingProstate-specific antigen screeningPSA testingProstate cancerScreening guidelinesBlack menBaseline prostate-specific antigenProstate-specific antigen valuesYears of follow-upProstate cancer deathProstate cancer mortalityScreening of menFull-text reviewComprehensive literature searchRandomized controlled trialsNon-black menAnnual screeningFrequency of testingIncrease overdiagnosisFollow-upProstateCohort studyCancer mortalityUnited States
2023
Daily Oral HIV Pre-exposure Prophylaxis Among Young Men Who Have Sex With Men in the United States: Cost-saving at Generic Drug Price
Amick A, Eskibozkurt G, Hosek S, Flanagan C, Landovitz R, Jin E, Wilson C, Freedberg K, Weinstein M, Kazemian P, Paltiel A, Ciaranello A, Neilan A. Daily Oral HIV Pre-exposure Prophylaxis Among Young Men Who Have Sex With Men in the United States: Cost-saving at Generic Drug Price. Clinical Infectious Diseases 2023, 78: 402-410. PMID: 37823865, PMCID: PMC10874274, DOI: 10.1093/cid/ciad566.Peer-Reviewed Original ResearchPre-exposure prophylaxisHIV incidenceRisk of HIVOral PrEPAnnual screeningHuman immunodeficiency virus (HIV) pre-exposure prophylaxisOral HIV pre-exposure prophylaxisHIV pre-exposure prophylaxisIncremental cost-effectiveness ratioHIV RNA levelsYoung menCost-effectiveness ratioAnnual HIVHigher discontinuationPrEP retentionAntiretroviral therapyDrug pricesHIV careLow adherenceLifetime horizonNew infectionsHIVIncidencePrEPRNA levelsExpanded or Risk Factor-Based Annual Screening for Hepatitis C Virus (HCV) Among Persons With HIV: Which Is the Best Approach?
Hao R, Brooks R, Zelenev A, Spinner G, Barakat L, Villanueva M. Expanded or Risk Factor-Based Annual Screening for Hepatitis C Virus (HCV) Among Persons With HIV: Which Is the Best Approach? Health Promotion Practice 2023, 24: 1009-1017. PMID: 37439817, DOI: 10.1177/15248399231169794.Peer-Reviewed Original ResearchConceptsHepatitis C virusRisk factor-based screeningElectronic medical recordsHIV clinicAnnual screeningC virusRisk factorsScreening siteAnnual screening ratesNew HCV diagnosesClinical decision support toolRisk factor assessmentPublic health expertsHCV testingHCV casesClinical decision supportHCV diagnosisHCV testScreening ratesProspective studyMedical recordsPositivity ratePositive casesUnprotected sexClinic
2021
1353. Gonorrhea and Chlamydia Testing and Case Rates Among Women Veterans in the Veterans Health Administration
Keddem S, Maier M, Gardella C, Borgerding J, Lowy E, Chartier M, Haskell S, Hauser R, Beste L. 1353. Gonorrhea and Chlamydia Testing and Case Rates Among Women Veterans in the Veterans Health Administration. Open Forum Infectious Diseases 2021, 8: 763-764. PMCID: PMC8643750, DOI: 10.1093/ofid/ofab466.1545.Peer-Reviewed Original ResearchMilitary sexual traumaWomen veteransChlamydia testingAge 25Chlamydia casesInfection rateVeterans Health Administration (VHA) careCase ratesIncidence of chlamydiaPredictors of testingRetrospective cohort studyCervical cancer screeningEvidence-based guidelinesHealth system factorsVeterans Health AdministrationIncidence of gonorrhoeaMental health diagnosesLow testing ratesSexual traumaSystem-level interventionsHigher infection rateEffective diagnostic testCohort studyPatient characteristicsAnnual screeningMay Measurement Month 2019: an analysis of blood pressure screening results from Lebanon
Najem RN, Halawi A, Tanios B, Ambriss R, Bikai RE, Partington G, Beaney T, Poulter NR, Abu Alfa A. May Measurement Month 2019: an analysis of blood pressure screening results from Lebanon. European Heart Journal Supplements 2021, 23: b92-b94. PMID: 34248434, PMCID: PMC8263084, DOI: 10.1093/eurheartj/suab037.Peer-Reviewed Original ResearchBlood pressureAntihypertensive medicationsLebanese populationImportant public health concernPrevalence of hypertensionBlood pressure readingsTreatment of hypertensionSilent killer diseasePublic health concernCross-sectional surveyOne-thirdHypertensive populationHypertension prevalenceDiastolic BPAnnual screeningBetter prognosisLifestyle factorsMean ageHigh prevalenceHypertensionMortality rateKiller diseasePressure readingsRapid interventionHealth concernWhen Is a Harm a Harm? Discordance between Patient and Medical Experts’ Evaluation of Lung Cancer Screening Attributes
Schapira MM, Rodriguez KL, Chhatre S, Fraenkel L, Bastian LA, Kravetz JD, Asan O, Akers S, Vachani A, Prigge JM, Meline J, Ibarra JV, Corn B, Kaminstein D. When Is a Harm a Harm? Discordance between Patient and Medical Experts’ Evaluation of Lung Cancer Screening Attributes. Medical Decision Making 2021, 41: 317-328. PMID: 33554740, DOI: 10.1177/0272989x20987221.Peer-Reviewed Original ResearchConceptsLung cancer screeningIncidental findingHarms of LCSVeterans Affairs Medical CenterRadiation exposureLung cancer deathsSignificant incidental findingsRoutine annual screeningProportion of participantsCross-sectional studyNon-Hispanic whitesPotential harmSDM discussionsAnnual screeningCancer deathCancer screeningPrimary careMortality reductionMedical CenterInvasive proceduresPatientsIndirect costsMost participantsScreening attributesOvertreatment
2019
The Potential Population-Level Impact of Different Gonorrhea Screening Strategies in Baltimore and San Francisco: An Exploratory Mathematical Modeling Analysis
Rönn M, Testa C, Tuite A, Chesson H, Gift T, Schumacher C, Williford S, Zhu L, Bellerose M, Earnest R, Malyuta Y, Hsu K, Salomon J, Menzies N. The Potential Population-Level Impact of Different Gonorrhea Screening Strategies in Baltimore and San Francisco: An Exploratory Mathematical Modeling Analysis. Sexually Transmitted Diseases 2019, 47: 143-150. PMID: 31842089, PMCID: PMC7012354, DOI: 10.1097/olq.0000000000001108.Peer-Reviewed Original ResearchConceptsAnnual screeningMost infectionsHigh-burden areasAdditional screening testFocused intervention strategiesCompartmental transmission modelRace/ethnicityPotential population-level impactCare cascadeBurden areasAcquisition riskScreen populationsScreening testPopulation-level impactInfectionSan FranciscoSurveillance dataPrevalence distributionScreening strategyInterventionIntervention strategiesSuch interventionsGonorrheaTime trendsMathematical modeling analysis
2010
Comparison of radiation exposure and associated radiation‐induced cancer risks from mammography and molecular imaging of the breasta)
O'Connor MK, Li H, Rhodes DJ, Hruska CB, Clancy CB, Vetter RJ. Comparison of radiation exposure and associated radiation‐induced cancer risks from mammography and molecular imaging of the breasta). Medical Physics 2010, 37: 6187-6198. PMID: 21302775, PMCID: PMC2997811, DOI: 10.1118/1.3512759.Peer-Reviewed Original ResearchConceptsBenefit/risk ratioMolecular breast imagingCumulative cancer incidenceCancer incidenceRisk ratioAge groupsExcess absolute risk (EAR) modelsAnnual digital mammographyAttributable risk modelRadiation-induced cancer riskBreast cancer incidenceBreast-specific gammaPositron emission mammographyBEIR VII reportRadiation-induced cancerDense breast tissueAbsolute risk modelsMBq FScreening groupAnnual screeningConventional dosesMBq TcLifetime riskBreast cancerAge 40Routine HIV Screening in France: Clinical Impact and Cost-Effectiveness
Yazdanpanah Y, Sloan CE, Charlois-Ou C, Le Vu S, Semaille C, Costagliola D, Pillonel J, Poullié AI, Scemama O, Deuffic-Burban S, Losina E, Walensky RP, Freedberg KA, Paltiel AD. Routine HIV Screening in France: Clinical Impact and Cost-Effectiveness. PLOS ONE 2010, 5: e13132. PMID: 20976112, PMCID: PMC2956760, DOI: 10.1371/journal.pone.0013132.Peer-Reviewed Original ResearchConceptsQuality-adjusted life monthsCost-effectiveness ratioQuality-adjusted life yearsGeneral populationRoutine HIVHIV prevalenceFrequent screeningLife expectancyAnnual HIV incidenceRoutine HIV screeningUndiagnosed HIV prevalenceHigh-risk groupHIV testing behaviorsInjection drug usersFrench general populationEpidemiology of infectionHIV screeningVoluntary HIVHIV infectionHIV testingAnnual screeningHIV incidenceMean ageHIV screenClinical impactTest and Treat DC: Forecasting the Impact of a Comprehensive HIV Strategy in Washington DC
Walensky RP, Paltiel AD, Losina E, Morris BL, Scott CA, Rhode ER, Seage GR, Freedberg KA, Investigators F. Test and Treat DC: Forecasting the Impact of a Comprehensive HIV Strategy in Washington DC. Clinical Infectious Diseases 2010, 51: 392-400. PMID: 20617921, PMCID: PMC2906630, DOI: 10.1086/655130.Peer-Reviewed Original ResearchConceptsHIV RNA levelsAntiretroviral therapyLife expectancyAdministration of ARTHuman immunodeficiency virus (HIV) epidemicART initiation strategiesHIV case detectionRNA levelsUndiagnosed HIV prevalenceCells/microLEarly case identificationInitial mean ageRegular screening programsHIV screeningHIV testAnnual incidenceAnnual screeningHIV prevalenceHIV transmissionHIV strategiesMean ageHIV epidemicCase detectionScreening programART efficacy
2007
Mammography screening of women in their 40s
Calvocoressi L, Sun A, Kasl SV, Claus EB, Jones BA. Mammography screening of women in their 40s. Cancer 2007, 112: 473-480. PMID: 18072258, PMCID: PMC3086941, DOI: 10.1002/cncr.23210.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAmerican Cancer SocietyAttitude to HealthBlack or African AmericanBreast NeoplasmsFemaleFollow-Up StudiesHealth Planning GuidelinesHumansInterviews as TopicMammographyMass ScreeningMiddle AgedNational Cancer Institute (U.S.)Practice Guidelines as TopicProspective StudiesUnited StatesWhite PeopleConceptsAmerican Cancer SocietyAnnual screeningNational Cancer InstituteMammography screeningWomen age 50 yearsMammography screening intervalWomen's beliefsAge 50 yearsNew screening guidelinesScreening intervalProspective studyScreening guidelinesScreening examACS recommendationsCancer SocietyRoutine screeningCancer InstitutePsychosocial factorsHealth historyScreening mammogramsMedical careAge groupsTelephone interviewsSame time periodWhite women
1994
Validation of the Gail et al. Model for Predicting Individual Breast Cancer Risk
Spiegelman D, Colditz GA, Hunter D, Hertzmark E. Validation of the Gail et al. Model for Predicting Individual Breast Cancer Risk. Journal Of The National Cancer Institute 1994, 86: 600-607. PMID: 8145275, DOI: 10.1093/jnci/86.8.600.Peer-Reviewed Original ResearchConceptsBreast cancer riskNurses' Health StudyIndividual breast cancer riskCancer riskBreast cancerHealth StudyGail et alAbsolute breast cancer riskPopulation-based studyMammography screening ratesExtensive family historyIndividual woman's riskPremenopausal womenAnnual screeningPrevention trialsScreening ratesRisk factorsCancer casesFamily historyTrial investigatorsStudy populationWoman's riskCancerPrevention effortsStudy period
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply